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Quantitative Serum HBV DNA levels During Different 
Stages of Chronic Hepatitis B Infection 
Chi-Jen Chu, Munira Hussain, and Anna S. F. Lok 
The goals of this retrospective study were to determine whether there is a threshold hepatitis 
B virus (HBV) DNA value associated with spontaneous or antiviral therapy-related hepatitis 
B e antigen (HBeAg) clearance. We also investigated whether there is an HBV DNA value 
that can be used for differentiating inactive carriers from patients with HBeAg-negative 
chronic hepatitis B. HBV DNA levels in sequential serum samples of 165 Chinese patients 
with different stages of chronic HBV infection were quantified by a polymerase chain 
reaction (PCR)-based assay. Our results showed that almost all of the patients (83%) who 
remained HBeAg-positive had HBV DNA levels that were persistently above lo5 copies/mL. 
Serum HBV DNA levels decreased by a mean of 3 loglo in patients with HBeAg loss, but 5 1% 
had levels above lo5 copies/mL at the time HBeAg first became undetectable. Mean serum 
HBV DNA levels were significantly lower in HBeAg-negative patients. HBV DNA value 
above lo5 copies/mL would exclude all inactive carriers, but 45% of patients with HBeAg- 
negative chronic hepatitis would also be excluded if testing were only performed at presen- 
tation and 30% would be excluded if testing were performed on 3 occasions. In conclusion, 
serum HBV DNA levels decreased significantly in patients with HBeAg loss, but there was no 
threshold HBV DNA level associated with HBeAg clearance. Given the fluctuating course of 
HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value 
for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis. 
(HEPATOLOGY 2002;36: 1408-1415.) 
he evaluation of patients with hepatitis B virus 
(HBV) infection has evolved from serologic to T molecular diagnostic assays. Using polymerase 
chain reaction (PCR) assays, the vast majority of patients 
with chronic HBV infection, including those who are 
hepatitis B e antigen (HBeAg) negative and hepatitis B e 
antibody (anti-HBe) positive have detectable HBV DNA 
in ~erum.~-7 The improvement in sensitivity of HBV 
Abbreviations: HBI.: hepatitis B virus; PCR, polymerase chain reaction; HBeAg, 
hepatitis B e antigen; anti-HBe, hepatitis B e antibody; AL T, alanine arninotrans- 
ferase; HBsAg, hepatitis B su$ace antigen; IFN, interferon. 
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DNA assays has improved our understanding of the 
pathogenesis and natural history of HBV infection and 
facilitated the monitoring of response to treatment, but it 
also has generated new questions and dilemmas.* 
Previous studies based on a single time point found 
that serum HBV DNA levels generally exceed lo5 cop- 
ies/mL among patients with HBeAg-positive chronic 
hepatitis and may be as high as 1O'O copies/mL.'-7 Serum 
HBV DNA levels tended to be lower (lo4 to los copies/ 
mL) among patients with HBeAg-negative chronic hepa- 
titis B (HBeAg-negative, anti-HBe-positive, elevated 
alanine aminotransferase [ALT])3,* and may be intermit- 
tently undetectable in non-PCR based assays.9,'O Until 
now, there have been very little data on what level of 
serum HBV DNA is associated with progressive liver dis- 
ease. Consequently, there is no consensus on the level of 
serum HBV DNA when treatment is indicated. 
A key question in the management of patients with 
HBeAg-positive chronic hepatitis B is to what level 
should serum HBV DNA be reduced to achieve sustained 
HBeAg seroconversion? To date, only 1 study had ad- 
dressed this issue. In a study of 23 patients who received 
lamivudine therapy, 6 (50%) of 12 patients whose serum 
HBV DNA decreased to <lo4 copieslmL developed 
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HBeAg seroconversion, versus none of 11 whose serum 
HBV DNA remained > 1 O4 copies/mL.l This study sug- 
gested that there may be a threshold HBV DNA level 
associated with lamivudine-induced HBeAg seroconver- 
sion. However, this study was based on a very small num- 
ber of patients. Thus, further studies are needed to 
validate this finding and to determine whether this 
threshold level applies to HBeAg seroconversion that oc- 
curs spontaneously or in association with other treatment. 
An arbitrary serum HBV DNA level of 1 O5 copies/mL 
has been proposed at the National Institutes of Health 
Workshop to differentiate chronic hepatitis B from an 
inactive carrier state (HBeAg-negative, persistently nor- 
mal ALT).12 A recent study in France found that 98% of 
the inactive carriers had HBV DNA levels < lo5 cop- 
ies/mL at presentation and 97% had an HBV DNA level 
persistently below lo5 copies/mL during a 1- to 6-year 
follow-up period.13 The investigators concluded that 
their results support the National Institutes of Health 
recommendation of 1 O5 copies/mL as a cutoff HBV DNA 
value for differentiating inactive carriers from patients 
with chronic hepatitis B, but this study did not include 
patients with HBeAg-negative chronic hepatitis B for 
comparison. Another study in Greece found that a cutoff 
value of lo5 copies/mL would lead to misclassification of 
13% of their patients with HBeAg-negative chronic hep- 
atitis B and possibly denial of treatment. They suggested 
that a cutoff HBV DNA level of 3 X lo4 copies/mL is 
more appropriate for differentiating inactive carriers from 
patients with HBeAg-negative chronic hepatitis B. l4  
However, HBV DNA was tested at 1 time point only in 
this study. Thus, the appropriate HBV DNA value for 
differentiating inactive carriers from patients with 
HBeAg-negative chronic hepatitis B remains to be deter- 
mined. 
We performed this retrospective study to measure 
quantitative HBV DNA levels in sequential serum sam- 
ples of patients with different stages of chronic HBV in- 
fection. Our goals were to determine (1) whether there is 
a threshold HBV DNA value associated with spontaneous 
or antiviral therapy-related HBeAg seroconversion, and 
(2) the HBV DNA value that should be used for differ- 
entiating inactive carriers from patients with HBeAg-neg- 
ative chronic hepatitis B. 
Patients and Methods 
Patients 
This was a retrospective study using stored sera from 
Chinese patients with chronic HBV infection seen in the 
Hepatitis Clinic, Queen Mary Hospital, Hong Kong, be- 
tween 1984 and 1992. Patients were seen every 3 to 6 
months, or more often if clinically indicated. At each visit, 
liver biochemistry and HBV serology, including hepatitis 
B surface antigen (HBsAg), HBeAg, and anti-HBe, were 
checked. Serum was collected and stored frozen at -20°C 
for HBV DNA testing. All patients who had had at least 3 
serum samples 1 year apart were studied. A total of 165 
patients were included. These patients were classified into 
5 groups: (1) persistently HBeAg-positive; (2) transient 
HBeAg loss/seroconversion: spontaneous (A) or inter- 
feron (1FN)-related (B); (3) sustained HBeAg lodsero- 
conversion: spontaneous (A) or IFN-related (B); (4) 
HBeAg-negative with persistent or intermittent elevation 
in ALT level; and ( 5 )  HBeAg-negative with persistently 
normal ALT (Table 1). Except for patients in groups 2B 
and 3B, none of the patients received antiviral therapy 
during the study period. 
DeJnition 
The upper limit of normal for serum ALT was 45 
IU/L. HBeAg loss was defined as disappearance of serum 
Table 1. Timing of Blood Samples in the 5 Groups of Patients Studied 
Interval Interval 
Between 1st and Between 2nd 
Number of 2nd Samples and 3rd Samples 
Group Patlents (mo) 2nd Sample (mo) 3rd Sample 
1. Persistently HBeAg-positive 27 2 1  2 2  Midway during FU 22 2 2 Last FU 
2. Transient HBeAg loss, spontaneous or 
3A. Sustained HBeAg loss, spontaneous 25 t 3 1  2 3  First HBeAg-negative 3 1  ? 3  Last FU 
38. Sustained HBeAg loss, IFN-related 24$ 20 i 3 First HBeAg-negative 40 2 4 Last FU 
4. HBeAg-negative with persistent or 
intermittently abnormal ALT 33 2a -c 2 Midway during FU 26 2 2 Last FU 
5. HBeAg-negative with persistently normal ALT 29 28 2 2 Midway during FU 34  ? 2 Last FU 
IFN-related 27* 2 5 2 3  First HBeAg-negative a 2 3  Reappearance of HBeAg 
~~ 
Abbreviations: HBeAg, hepatitis B e antigen; FU, follow-up; IFN, interferon; ALT, alanine aminotransferase. 
*Fourteen spontaneous, 13 IFN-related, 13 developed anti-HBe. 
tEighteen developed anti-HBe. 
+Nineteen developed anti-HBe. 
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HBeAg in a patient who previously had been HBeAg- 
positive. HBeAg seroconversion was defined as disappear- 
ance of HBeAg accompanied by the development of anti- 
HBe. Sustained HBeAg losslseroconversion was defined 
as maintenance of this phenomenon for at least 1 year and 
until the last visit, with HBeAg/anti-HBe retested at least 
twice per year. HBeAg losdseroconversion that occurred 
within 1 year after stopping IFN therapy was defined as 
IFN-related. Sustained biochemical remission was de- 
fined as persistently normal serum ALT from 6 months 
after first HBeAg loss until the last visit. 
Hepatitis B Serology 
The hepatitis B serologic markers HBsAg, HBeAg, and 
anti-HBe were tested using commercially available en- 
zyme-linked immunosorbent assay kits from Abbott Lab- 
oratories (North Chicago, IL). 
Quuntajication of Serum HBV DNA Levels 
Serum HBV DNA levels were quantified using the 
Cobas Amplicor HBV Monitor kits according to the 
manufacturer's instructions (Roche Molecular Systems, 
Inc., Branchburg, NJ).*~7,~5-l~ The lower limit of detec- 
tion of this assay is 200 copies/mL (approximately 0.001 
pg/mL) with a range of linearity up to 10' copies/mL. 
Samples from patients who were HBeAg-positive were 
initially tested after a 1 in 1O0,OOO dilution; samples with 
undetectable HBV DNA were retested without dilution. 
Samples from patients who were HBeAg-negative were 
initially tested undiluted; samples with HBV DNA results 
>lo6 copieslml were retested after 1 in 100,000 dilu- 
tion. An arbitrary value of 100 copies/mL was assigned to 
samples with undetectable HBV DNA for statistical com- 
parisons. 
HBV Genotyping 
The first available sample from each patient was used 
for HBV genotyping using a line-probe assay (Inno-Lipa 
HBV genotyping assay; Innogenetics, Inc., Ghent, Bel- 
gium) .18-20 All necessary precautions to prevent cross- 
contamination were observed, and negative controls were 
included at each step. To  validate the results of line probe 
assay, 10% randomly selected samples of genotypes B and 
C and all samples with genotype A or D were sent for 
bidirectional automated sequencing at the DNA sequenc- 
ing core facility, University of Michigan Medical Center, 
using the standard protocol for the Applied Biosystems 
DNA sequencer 377 (Perkin Elmer Corp., Foster City, 
CA). Sequencing results were compared with published 
sequences to ascertain HBV genotypes.21,22 HBV geno- 
type could be determined by line-probe assay in all 
patients who had detectable HBV DNA by PCR. Com- 
parison between results of direct sequencing and the line- 
probe assay showed 100% concordance. 
Precore Stop Codon Variant (G189J) and Core 
Promotor Variant (AI~QT, G1764A) 
Serial samples from patients with sustained HBeAg 
seroconversion (group 3) and initial samples of HBeAg- 
negative patients (groups 4 and 5 )  were tested for precore 
(PC) stop codon ( (21894)  and core promotor (CP) 
(A1762T, GI76&) variants using Inno-Lipa precore/core 
promotor kits (Innogenetics, Inc.).'9,20 Except for the 
primers, the procedure was similar to that for HBV geno- 
typing. All samples with indeterminate results and 20% of 
randomly selected samples with PC and/or CP variant 
were sent for direct sequencing as described above. Inde- 
terminate results were obtained in only 2% of samples in 
the PC and 9% in the CP region using the line-probe 
assay. Of the samples that could be typed, the concor- 
dance between the line-probe assay and sequencing was 
99%. The line-probe assay was more sensitive in detecting 
mixed sequences than direct sequencing. 
statistical Analyses 
Results were expressed as mean i standard error. Data 
were entered into an Excel database and analyzed using 
SPSS version 9.0 software package (SPSS, Inc., Chicago, 
IL). Statistical analyses were performed using x2 and Fish- 
er's exact test for categorical variables. Paired or unpaired 
Student's t test or one-way ANOVA with Tukey test was 
used for continuous variables as appropriate. Results were 
considered statistically significant at P < .OS. 
Results 
The demographics, baseline liver histology, results of 
HBV genotyping, and serial quantitative HBV DNA and 
ALT values are summarized in Tables 2 and 3. 
Group I:  Persistently HBeAg-Positive, n = 27 
Serum HBV DNA levels varied from 1O5-l0 copieslml 
with a slight (<1 loglo) decline during a mean follow-up 
of 43 t 3 months (range, 24 to 88 months) (Fig. 1A). 
There was no correlation between serum HBV DNA and 
ALT levels. HBV DNA levels above lo5 copies/mL were 
observed in 96% of the samples. None of the patients in 
this group had HBV DNA levels persistently below lo5 
copieslml. 
Group 2: Transient HBeAg Loss/Seroconversion: 
Spontaneous or IFN-Related, n = 27 
Serum HBV DNA levels decreased by a mean of 3 
loglo to 103-8 copies/mL when HBeAg first became unde- 
tectable and increased by a mean of 2 loglo with the reap- 
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Table 2. Demographics, Baseline Histology, and HBV Genotypes of Patients Studied 
Histology HBV Genotypes Gender Mean Age Number (%) of Patients 
Group (M/F) (Yr) With Liver Biopsies (NS/CH/cirrhosis) (A/B/C/D) 
1 20/ 7 24 t 1 
2 22/5 32 2 2 
3A 12/13 29 t 2 
3B 17/7 29 t 1 
4 2419 34 f 2 










O/ 12/ 13/0 
01 11/12/ 1 
0/12/19/0 
1/11/7/1 
~~~~~~ ~ ~~ 
Abbreviations: HBV, hepatitis B virus; NS, nonspecific changes; CH, chronic hepatitis. 
pearance of HBeAg (Fig. 1B). There was no difference in 
absolute value or degree of decline of the HBV DNA level 
between patients with spontaneous or IFN-related tran- 
sient HBeAg loss. 
Group 3: Sustained HBeAg LossLSeroconversion: 
Spontaneous (A), n = 25, or IFN-Related (B), 
n = 24 
HBV DNA Level and HBeAg Loss. Thirty-seven 
(76%) of these 49 patients developed anti-HBe, simulta- 
neous with the loss of HBeAg in 26 patients and after a 
mean of 10 _f 3 months (range, 1 to 30 months) after 
HBeAg first became undetectable in the remaining 1 1  
patients. Serum HBV DNA levels decreased by a mean of 
3 loglo to 10”’ copies/mL when HBeAg first became 
undetectable (Fig. 1 C). HBV DNA levels above 1 06, 1 05, 
and I O4 copieslml were found in 38%, 5 1 %, and 63% 
patients, respectively, at the time when HBeAg first be- 
came undetectable. After HBeAg loss, a further decline in 
serum HBV DNA levels by 1 to 1.5 loglo was observed 
during a mean follow-up of 35 t 3 months (range, 12 to 
81 months). 
Baseline HBV DNA levels were similar among the 3 
groups of patients (1 to 3) who were HBeAg-positive at 
presentation (mean, 7.9 to 8.3 loglo copieslml). HBV 
DNA levels at the time when HBeAg first became unde- 
tectable were comparable in groups 2 and 3 patients, 
mean levels being 4.98 2 0.21 and 4.99 2 0.24 loglo 
copieslml, respectively. Within each of the 2 groups of 
patients with HBeAg loss (2  and 3),  HBV DNA levels at 
the time when HBeAg first became undetectable were 
similar in patients with spontaneous versus IFN-related 
HBeAg loss, and in patients with or  without anti-HBe 
seroconversion (Table 4). 
HBV DNA Level and Sustained Biochemical Re- 
mission. Thirty-eight (78%) patients had sustained bio- 
chemical remission after HBeAg loss. Patients with 
sustained biochemical remission had a lower HBV DNA 
level at the time of HBeAg loss (mean, 4.80 ? 0.26 vs. 
5.67 t 0.53 loglo copies/mL) and at the last follow-up 
visit (mean, 3.74 t 0.18 vs. 4.07 t 0.56 loglo copies/ 
mL), but these differences were not statistically signifi- 
cant. Figure 2 shows a patient who had sustained 
biochemical remission after HBeAg seroconversion, and 
Fig. 3 shows a patient with persistently elevated ALT after 
HBeAg seroconversion. 
HBV DNA Level and Selection of Precore or Core 
Promotor Variants. Of the 49 patients with sustained 
HBeAg losslseroconversion, 16 (33%) had core pro- 
moter and 3 (6%) had precore variant as the dominant 
sequence at presentation, whereas 17 (35%) had core 
promotor and 16 (33%) had precore variant as the 
dominant sequence when HBeAg first became unde- 
tectable. Serum HBV DNA levels at the time of HBeAg 
loss were comparable between patients with and with- 
out precore variants (Table 5 )  and in patients with and 
without core promotor variants (4.87 t 0.41 vs. 
5.40 _f 0.32 loglo). The prevalence of precore (13 of 38 
Table 3. Serial HBV DNA and ALT Levels of Patients Studied 
1st Sample 2nd Sample 3rd Sample 
Number (%) With Mean Log, Change in Mean Loglo Change Mean 
(IU/L) 
Mean Log,, HBV Undetectable Mean ALT HBV DNA From 1st Mean ALT in HBV DNA From ALT 
2nd Sample Group DNA (Copies/mL) HBV DNA ( W L )  Sample ( W L )  
1 8.37 t- 0.22 0 (0) 149 rt 45 -0.39 i_ 0.33 69 L 19 -0.28 -t 0.28 93 2 22 
2 7.86 t 0.32 0 (0) 210 ? 49 -2.87 ? 0.35 80 F 18 1.59 2 0.37 87 i 14 
3A 8.31 t- 0.28 0 (0) 105 t 23 -3.10 2 0.40 7 1  -C 19 -1.44 I+_ 0.32 27 Z 4 
38 7.74 t- 0.35 0 (0) 108 2 15 -2.96 2 0.34 69 rt 19 -0.91 2 0.40 29 t- 3 
4 5.1 7 2 0.33 2 (6) 118 t 23 0.39 _f 0.29 190 _f 35 -0.81 2 0.33 85 -C 21 
5 3.10 ? 0.17 9 (31) 18 5 2 0.18 t- 0.17 17 t 1 -0.16 t- 0.13 20 ? 1 
~~~~ ~ ~ 
Abbreviations: HBV, hepatitis B virus; ALT, alanine aminotransferase. 
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Fig. 1. Log,, HBV DNA levels of patients during follow-up. (A) Group 
1, HBeAg-positive patients; (B) group 2,  HBeAg-positive patients with 
transient HBeAg loss; (C) group 3, HBeAg-positive patients with sus- 
tained HBeAg loss: (a) spontaneous and (b) IFN-related; (D) group 4, 
HBeAg-negative patients with persistent or intermittently abnormal ALT; 
and (E) group 5, HBeAg-negative patients with persistently normal ALT. 
The box plots showed the loth,  25th, 50th, 75th, and 90th percentiles 
and outliers (circles). Mean HBV DNA level is indicated as a dotted line 
within the box. The lower limit of detection (200 copies/mL) is expressed 
as a dash-dot line. 
.A- M- -t F - 
1 st 2nd 3rd 
sample 
vs. 3 of 11) and core promotor (12 of 38 vs. 5 of 11) 
variants at the time when HBeAg first became unde- 
tectable was similar between patients with and without 
sustained biochemical remission. 
Group 4: HBdg-Negative With Pershmt or 
Intmittentl  AbnomalALT, n = 33 
Comparedlvith patients who were HBeAg-positive, 
this group of patients had significantly lower serum 
HBV DNA levels; mean, 5.2 loglo versus 8.4 loglo 
copies/mL (P < .OO 1). There was a wide range in HBV 
DNA levels at presentation (1 03-8 copies/mL) (Fig. 
1 D) and during the course of follow-up (Fig. 4) .  About 
half (47%) of the samples had HBV DNA levels less 
than lo5 copies/mL. HBV DNA levels persistently 
greater than lo5, lo4, and lo3 copies/mL, were found in 
33%, 58%, and 82% patients, respectively. Twenty- 
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Table 4. Serial HBV DNA levels in GrouD 3 Patients Who Lost HBeAg With and Without HBeAp! Seroconversion 
HBeAg Seroconversion HBeAg Loss Only P Value 
Number of patients 
Mean 2 SEM HBV DNA (loglo copies/mL) 
A t  presentation 
At the time of HBeAg loss 
Last follow-up 
37 
8.12 -t 0.23 
5.11 ? 0.26 
3.78 2 0.20 
12 
7.68 2 0.69 
4.55 2 0.55 




Abbreviations: HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; NS, not significant. 
three (70%) patients had at least 1 sample with an 
HBV DNA level > lo5 copieslml. 
Nine patients of this group had persistently abnormal 
ALT levels during the follow-up period. Patients with 
persistently abnormal ALT levels tend to have a higher 
HBV DNA level at presentation as compared with pa- 
tients with intermittently abnormal ALT level (6.1 l * 
0.76 loglo copies/mL vs. 4.82 ? 0.34 loglo copies/mL, P 
= .O8). At presentation, the CP variant as the dominant 
sequence was found in 59% ofpatients and the PC variant 
was found as the dominant sequence in 36% of patients 
(Table 6). HBV DNA level was comparable between pa- 
tients with and without the PC variant (5.52 2 0.30 vs. 
5.30 2 0.48 loglo copieslml). 
Group 5: HBeAg-Negative With Persistently Normal 
A L T , n = 2 9  
The HBV DNA level in this group was significantly 
lower than that of patients in group 4,  the mean HBV 
DNA level at presentation being 3.1 loglo copies/mL (P 
< .OOl ) .  At presentation, the CP variant as the dominant 
sequence was found in 30% of patients and the PC variant 
as the dominant sequence was found in 50% of patients 
(Table 6). HBV DNA levels remained stable during a 
mean follow-up period of 62 ? 3 months (range, 41 to 92 
months). Twenty-six (90%) patients had detectable HBV 
. .  HEeAg + +  t -  
Anti-HBe - +  + + +  
PC 1896 G G>A G>A 
CP 1762 1764 AG AG>TA AG>TA 
lo  1 
0 '  , 












Fig. 2. HBV DNA and ALT levels in one patient with sustained bio- 
chemical remission after HBeAg seroconversion. 
DNA in at least 1 of their 3 samples, and 15 (52%) had 
persistently detectable serum HBV DNA. All of the sam- 
ples had HBV DNA levels lower than lo5 copies/mL. 
Only 2 (7%) patients had HBV DNA levels persistently 
higher than lo4 copies/mL. 
Discussion 
In accordance with previous reports,'-' we found that 
more than 90% of HBeAg-positive patients had serum 
HBV DNA levels that could be detected by non-PCR 
assays, which have detection limits of lo5" copies/mL. In 
this study, the correlation between HBV DNA and ALT 
levels in HBeAg-positive patients was poor, possibly re- 
lated to immune tolerance secondary to perinatal infec- 
tion in many of our patients. 
A previous small-scale study on lamivudine-treated pa- 
tients suggested that HBV DNA levels must be reduced to 
less than lo4 copies/mL for HBeAg seroconversion to 
occur.' Our results showed a wide range in HBV DNA 
levels ( copies/mL) at the time HBeAg first became 
undetectable, implying that there is no threshold HBV 
DNA level for HBeAg clearance/seroconversion. This ob- 
servation was true for spontaneous as well as IFN-related 
HBeAg clearance/seroconversion. Because our samples 
were collected in the prelamivudine era, we cannot ascer- 
+ + + - - -  
Anti-HBe - . .  + + +  + t 
H W  
P C I m  G O A  WA 
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Fig. 3. HBV DNA and ALT levels in one patient without biochemical 
remission after HBeAg seroconversion. 
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Table 5. Serial HBV DNA levels in Group 3 Patients Who 
lost HBeAg With and Without Selection of 
Precore Giss6A Mutation 
With Selection Without Selection 
of PC Variant of PC Variant P Value 
~ 
Number of patients 16 33 
Mean 2 SEM HBV DNA 
(loglo copies/mL) 
Sample 1 8.41 +- 0.29 7.82 Z 0.35 NS 
Sample 2 5.62 -C 0.32 5.00 2 0.35 NS 
Sample 3 4.20 +- 0.48 3.64 ? 0.15 NS 
Abbreviations: HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; PC, precore; 
NS, not significant. 
tain whether our results can be generalized to nucleo- 
s(t)ide therapy-related HBeAg clearance. All of our 
patients were ethnically Chinese, most of whom had peri- 
natally acquired HBV infection. Thus, it is not clear 
whether our results can be generalized to patients with 
adult-acquired HBV infection. 
Interestingly, we found no difference in HBV DNA 
levels at the time HBeAg first became undetectable be- 
tween patients with transient and sustained HBeAg loss, 
indicating that serum HBV DNA level at this time point 
is not a good predictor of durability of HBeAg loss. In 
addition, our study showed that HBV DNA levels at the 
time of HBeAg loss were similar in patients with and 
without anti-HBe seroconversion. In patients with sus- 
tained HBeAg loss, there was a further reduction in HBV 
DNA levels during follow-up. However, HBV DNA re- 
mained detectable by PCR in 96% of patients 35 ? 3 
months after sustained HBeAg loss. 
As in our previous r e p o r t ~ , 9 . ~ ~ - ~ ~  we found that patients 
with sustained HBeAg loss were more likely to be infected 
with HBV genotype B, that HBeAg clearance can occur in 
the absence of detectable mutations that abolish or de- 
crease HBeAg production, and that selection of precore or 
.~ . .  . ~ HBeAg 
Anti-HBe + + +  t + t i  t 
PC 1896 G G A,G 
CP 1762 1764 AG>TA TA,AG AG 
$ 1  












Fig. 4. HBV DNA and ALT levels in one patient with HBeAg-negative 
chronic hepatitis B. 
Table 6. Core Promotor/Precore Sequence of Group 4 and 5 
Patients a t  Presentation 
Group 4 Group 5 
Number of patients 33 29 
HBV DNA-positive by PCR 31 (94%) 20 (69%) 
CP (1762, 1764) sequence 
WT only 6 (19%) 11 (55%) 
WT > CP Var 6(19%) 1(5%) 
CP Var only 16 (52%) 6 (30%) 
CP Var > WT 2'(7%) O(O%) 
Other mutations* 1(3%) 2(10%) 
PC (1896) sequence 
WT only 15 (48%) 7 (35%) 
WT > PC Var 4 (13%) 2 (10%) 
PC Var > WT 3 (10%) 4 (20%) 
Other point mutation 1(3%) 1(5%) 
PC Var only 8 (26%) 6 (30%) 
7 (23%) 6 (30%) WT-dominant sequence in both CP and PC regions 
Abbreviations: CP, core promotor: PC, precore; HBV, hepatitis B virus; PCR, 
polymerase chain reaction; W, wild type: CP Var, A1762T GITgj4A; PC Var, GIsg6A. 
*Including single mutation AIT6*T and G1764A, deletions, and other point 
mutations. 
core promotor variants after HBeAg loss was not neces- 
sarily associated with a higher HBV DNA or ALT level. In 
accordance with recent l i t e r a t ~ r e , ~ ~  not all patients with 
sustained HBeAg seroconversion had sustained biochem- 
ical remission. Although 36% of the patients without sus- 
tained biochemical remission had a transient ALT flare, 
the remaining 64% had intermittent or persistently ab- 
normal ALT values. The latter pattern explains why some 
patients develop progressive liver disease despite sustained 
HBeAg seroconversion. 
The National Institutes of Health workshop on man- 
agement of hepatitis B proposed that a serum HBV DNA 
level of lo5 copies/mL be used to differentiate chronic 
hepatitis B from an inactive carrier state.12 Our results 
showed that a HBV DNA value above lo5 copies/mL 
would exclude all inactive carriers but also 45% of pa- 
tients with HBeAg-negative chronic hepatitis if testing 
were only performed at presentation and 30% if testing 
were performed on 3 occasions. Decreasing the cutoff 
value to 3 X lo4 copies/mL would misclassify 7% of 
inactive carriers and 30% of patients with HBeAg-nega- 
tive chronic hepatitis if testing were only performed at 
presentation. Given the variable course of HBeAg-nega- 
tive chronic hepatitis B, retesting on more than one occa- 
sion helps in differentiating patients with HBeAg- 
negative chronic hepatitis from inactive carriers, but no 
single HBV DNA value reliably differentiates these 2 
groups. In accordance with other reports,'3 we found that 
serum HBV DNA remained detectable in the vast major- 
ity of inactive carriers, but HBV DNA levels tend to be 
lower and to remain stable over a 5-year follow-up period. 
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In summary, we found that serum HBV DNA levels 
were very high ( lO5- I0  copieslml) in HBeAg-positive pa- 
tients. Serum HBV DNA levels decreased by a mean of 3 
loglo in patients who had spontaneous or IFN-related 
HBeAg loss, but there was no threshold HBV DNA level 
associated with HBeAg clearance. Serum HBV DNA 
level at the time of HBeAg loss was not a predictor of 
durability of HBeAg loss. A further decline in serum HBV 
DNA levels was observed in patients with sustained 
HBeAg loss regardless of anti-HBe seroconversion. Serum 
HBV DNA levels were significantly lower in HBeAg-neg- 
ative patients, but levels as high as 109 copies/mL were 
detected. Although all of the inactive carriers had HBV 
DNA levels that were persistently below lo5 copies/mL, 
only 33% of patients with HBeAg-negative chronic hep- 
atitis had HBV DNA levels that were persistently above 
lo5 copiesiml. Given the fluctuating course of HBeAg- 
negative chronic hepatitis B, it is not possible to define a 
single cutoff HBV DNA value for differentiating inactive 
carriers from patients with HBeAg-negative chronic hep- 
atitis. 
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